EPISODE · Jul 22, 2022 · 9 MIN
Tolebrutinib Trials Paused Over Safety Concerns & Setback for MS Spasticity Treatment
from MS News & Perspectives · host MS News Today
Multiple Sclerosis News Today’s multimedia associate, Price Wooldridge, discusses how new U.S. enrollments in Phase 3 trials of tolebrutinib for MS have been paused due to some reports of liver injury.He also reads “Trial Results a Setback for US Approval of Nabiximols for MS Spasticity” from Ed Tobias’ column “The MS Wire.”=================================== Are you interested in learning more about multiple sclerosis? If so, please visit:https://multiplesclerosisnewstoday.com/ =====================================To join in on conversations regarding multiple sclerosis, please visit:https://multiplesclerosisnewstoday.com/forums/
Embed this episode
NOW PLAYING
Tolebrutinib Trials Paused Over Safety Concerns & Setback for MS Spasticity Treatment
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.